Sobre

They have all of those things and vaginal hormones are safer them, don't affect your milk supply and should be used commonly. And every gynecologist knows this, but they forgot to tell all of us and they forgot to tell us that actually vaginal hormones were safe. So dying less if you use vaginal hormones than if you don't.
In a 90-day open label trial of 306 testosterone deficient men using two actuations (11mg) of the drug applied three times daily, results were reported for 73 men at day 90. The product is provided in a metered pump that supplies 5.5 mg of testosterone per actuation. An intranasal testosterone gel applied topically into the nose was approved by the FDA in 2014. The progressive hydration tablet with a matrix containing 30 mg of testosterone is placed in position on the gum above the right or left canine and is held in position for approximately 30 seconds.
Often, doctors will order blood tests to check estrogen, progesterone, thyroid hormones, and testosterone levels simultaneously. And even in that study, women who only took vaginal hormones had no cancer risk, no breast cancer risk that was published on. Since the FDA warning in 2015, other studies have failed to demonstrate a risk of cardiovascular events in patients on testosterone therapy. Although the committee reviewing the evidence concluded that there was not enough data to definitively state that testosterone therapy posed a significant cardiovascular risk, the FDA nonetheless required testosterone product manufacturers to add information to the labeling about a possible increased risk of myocardial infarction and cerebrovascular accidents in patients using testosterone therapy. Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. Men with total testosterone level 315 ng/dL declined from 100% at 4 weeks to 86%, 75%, and 14% by 12, 20, and 24 weeks, respectively.Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. Administration of 750 mg of IM testosterone undecanoate at weeks 0, 4, and every 10 weeks thereafter maintained total testosterone levels between 300-1,000 ng/dL for 94% of men.438 No men experienced maximal values Adverse Effects.
So let's talk about testosterone. You've got full body estrogen, full body progesterone, you've got vaginal estrogen and full body testesterone. The progesterone keeps the lining thin, prevents uterine cancer.
Improvements in sex drive were also assessed in another meta-analysis performed by Bolona et al.298  Using a variety of measures, the authors demonstrated improvement with a pooled effect of 1.31 (31% increase in sex drive) among men treated with testosterone, with greater improvements noted among men with lower baseline testosterone levels. While the Panel is unable to quantify what percentage of men with ED and testosterone deficiency experience clinically meaningful improvements in erectile function (in contrast to statistically significant improvements) or the ability to achieve a functional erection, it is clear that some men will have improvement in erectile function with testosterone therapy. In trials, patients with low testosterone have demonstrated statistically significant improvements in erectile function, anemia, BMD, lean body mass, and depressive symptoms. Only one man in the treatment group was diagnosed with prostate cancer during the study period; two more who had been on treatment and one on placebo were diagnosed in the following year.229 The literature indicates that men with lower baseline testosterone levels are more likely to experience PSA level increases. In 2013, the AUA published the Early Detection of Prostate Cancer Guideline,222 which makes no specific statements about PSA screening in men with testosterone deficiency or in men on testosterone therapy.
It's a great drug to take every day, a small dose every day for urinary symptoms, and vaginal hormones help with urinary symptoms. So that's where we love IUDs and things like that because they don't alter your body's formation of these hormones. And in fact, we've done even more research that shows very few of these patients are actually offered a vaginal hormone therapy and it's being really underused. I mean, again, maybe these women are sexually active, they're more active, they're more interested in their health so that we see these health outcomes, but you shouldn't suffer. And if you have any urinary symptoms, frequency, urgency, leakage, any pain with sex, dryness, if you've had a UTI, you should be considered for vaginal hormones.
Although the absolute risks of POME and anaphylaxis require ongoing study, data from 342 patients undergoing 3,022 injections (1,000 mg in 4 mL) over a period of 3.5 years demonstrated that POME occurred after 1.9% of injections (12% of patients experienced at least one POME), with coughing episodes lasting 1-10 minutes in duration.443 All episodes were managed conservatively in the clinic, with no supplemental oxygen required. For trough total testosterone values 300 ng/dL are achieved at the end of an injection period. In contrast to topical agents where a percentage of men have difficulty achieving therapeutic levels within standard dosing ranges, injectable testosterone preparations are able to achieve therapeutic levels in almost any clinical scenario. In a study directly comparing the pharmacokinetics of 2 doses of SQ testosterone enanthate injected weekly (50 or 100 mg) and 1 concentration of IM testosterone enanthate injected once (200 mg), the IM testosterone achieved the highest peak testosterone (mean 2,261 ng/dL) followed by SQ 100 mg (1,345 ng/dL) and SQ 50 mg (622 ng/dL).437 The time-to-peak level was slightly faster with IM testosterone (33 hours) compared to SQ 100 mg (36 hours) and SQ 50 mg (45 hours). The pharmacokinetics of short-acting testosterone therapy depends on the dose, interval, and method of delivery (SQ versus IM). Testosterone is released from the tablet in a manner similar to the normal daily rhythm of endogenous testosterone, with serum levels rising rapidly after buccal absorption and peak levels reached by the second 12-hour daily dose. One of the oral alternatives for testosterone therapy is the 30 mg sustained-release muco-adhesive buccal pellet applied to the upper gums above the incisor teeth twice daily.432